We are thrilled to celebrate a significant achievement in global health and pharmaceutical innovation: Senegal has become the first Francophone country – and seventh country – in Africa to attain Maturity Level 3 (ML3) certification from the World Health Organization (WHO) for medicine regulation. This recognition marks a major step forward for the country’s regulatory capacity and the broader African continent’s ability to ensure high-quality medicines that meet international standards.
Why This Matters
Regulatory systems are the backbone of public health, ensuring that medical products are safe, effective, and of high quality. Efficient regulatory systems foster innovation, market access, and improved healthcare outcomes.
To measure regulatory effectiveness, the WHO Global Benchmarking Tool (GBT) evaluates national systems against more than 250 indicators, assigning maturity levels from ML1 to ML4.
Achieving ML3 means that Senegal’s regulatory framework is now classified as ‘stable, well-functioning, and integrated,’ capable of ensuring that all medical products, whether locally produced or imported, comply with rigorous global quality and safety standards. This achievement is a recognition of the country’s sustained investment towards strengthening its health system and its commitment to ensuring that the highest standards of safety, efficacy and quality are applied to medicines and other medical products. It also marks a critical milestone in advancing Africa’s self-reliance in pharmaceutical production and reducing dependence on external suppliers.
Other African countries at ML3 include Egypt, Ghana, Nigeria, South Africa, Tanzania, and Zimbabwe.
Impact on Clinical Research & Pharmaceutical Development
One of the key aspects evaluated under the GBT framework is ‘Clinical Trials Oversight’, a crucial component in advancing medical research and drug development.
At Pharmalys Ltd, we recognise the potential this milestone unlocks for clinical research, regulatory advancements, and pharmaceutical development in Africa. A stronger regulatory framework ensures smoother clinical trial processes, faster market access for innovative therapies, and improved healthcare outcomes. As a company committed to advancing clinical research in Africa, we celebrate this achievement and look forward to contributing to the next phase of Senegal’s regulatory and pharmaceutical growth.
A Win for Senegal, Africa, and Global Health
We extend our congratulations to Senegal’s Ministry of Health, the Agence Sénégalaise de Réglementation Pharmaceutique (ARP), and all stakeholders who made this achievement possible. Their dedication sets a powerful precedent for other nations striving for regulatory excellence.
This is more than just a milestone for Senegal— it is a win for Africa and the global health community.
Ndeye SECK
Clinical Project Manager | Regulatory Affairs & Study Start-Up Team Lead
